The role of integrins in the pathogenesis of inflammatory bowel disease: Approved and investigational anti-integrin therapies.

"DISCLOSURES Iris Dotan served as a speaker, consultant, and/or advisory board member for Genentech, Abbvie, Pfizer, Janssen, Takeda, Ferring, Roche, Rafa Laboratories, Falk Pharma, Given Imaging, Protalix, Medtronix, Celltrion, and Neopharm. Matthieu Allez received honoraria from Abbvie, MSD, Janssen, Takeda, Pfizer, Celgene, Roche/Genentech, Novartis, Ferring, Tillots, Mayoli, and UCB. Silvio Danese served as a speaker, consultant, and/or advisory board member for Abbvie, Ferring, Hospira, Johnson and Johnson, Janssen, Merck, MSD, Takeda, Mundipharma, Pfizer Inc, Tigenix, UCB Pharma, Vifor, Biogen, Celgene, Allergan, Celltrion, Sandoz, and Boehringer Ingelheim. Mary Keir, Jacqueline McBride, and Swati Tole are all employees of Genentech, a member of the Roche Group."

"This review was supported by Genentech Inc, a member of the Roche Group. Third‐party medical writing and editorial support (formatting, proofreading, and copyediting) was provided by ApotheCom, San Francisco, CA, and was funded by F. Hoffmann‐La Roche, Ltd."